Chromophobe renal cell cancer--review of the literature and potential methods of treating metastatic disease.
Chromophobe renal cell carcinoma (ChRCC) is a subtype of renal cell carcinoma (RCC). ChRCC is diagnosed mainly in 6th decade of life. An incidence of ChRCC is similar in both men and woman. Eighty six percent of ChRCCs cases are diagnosed in stage 1 or 2. Prognosis of ChRCC is better than in other types of RCC. Five- and 10-year disease free survival (DFS) for ChRCC was 83.9% and 77.9%, respectively. Expression of immunohistological markers: cytokeratins (CK), vimentin, epithelial membrane antigen (EMA), CD10 could be potentially helpful in diagnosis of different subtypes of RCC. From all conventional RCC, CD 117 was detected (overexpression) in membrane of cells ChRCC.Overexpression of CD117 on cellular membranes of ChRCC could be a potential target for kinase inhibitors like: imatinib, dasatinib, nilotinib. The potential targets for other kinase inhibitors (sunitinib and sorafenib) in ChRCC seem to be VEGFR and PDGFR. On the basis for formulating research hypotheses which should be verified by prospective studies.
Stec
Rafał
R
Department of Oncology, Military Institute of Health Services, Warsaw, Poland. drrafals@wp.pl
Grala
Bartłomiej
B
Maczewski
Michał
M
Bodnar
Lubomir
L
Szczylik
Cezary
C
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000032:analysis; D002292:Carcinoma, Renal Cell; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D007680:Kidney Neoplasms; D008297:Male; D019009:Proto-Oncogene Proteins c-kit / Q000378:metabolism*
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D019009:Proto-Oncogene Proteins c-kit